智通财经网·2026-02-24 13:43Core Viewpoint - Novo Nordisk plans to significantly reduce the official pricing of its weight loss drugs Wegovy and Ozempic in the U.S. market to capture a larger share in the obesity treatment sector, with a price cut of up to 50% [1] Pricing Strategy - The new monthly price for the semaglutide drug series will be set at $675, compared to Eli Lilly's Zepbound, which is priced at $1,086.37 per month [1] - The price reduction applies to wholesale acquisition costs and does not reflect the complex rebate system in the U.S. market [1] Impact on Patients - The price cut is expected to alleviate out-of-pocket costs for insured patients, particularly those with high-deductible plans, where out-of-pocket expenses are closely tied to official pricing [2] - Patients using Zepbound and Wegovy may see their monthly out-of-pocket costs drop to as low as $25 [1] Market Context - Approximately one-third of insured workers opted for high-deductible health plans paired with health savings accounts last year, indicating a significant market segment that will benefit from the price reduction [2] - Less than half of large employers provide insurance coverage for GLP-1 weight loss drugs like Wegovy, highlighting the potential for increased adoption following the price cut [2] Implementation Timeline - The new pricing will take effect on January 1 of the following year, allowing payers time to adjust to the changes [2] - The price reduction is independent of the discounts negotiated by the U.S. government for Medicare patients [2]